Wall Street Pummels Turning Point Therapeutics Inc. (TPTX) After Recent Earnings Report – News Heater
Home  »  Business   »  Wall Street Pummels Turning Point Therapeutics Inc...

Wall Street Pummels Turning Point Therapeutics Inc. (TPTX) After Recent Earnings Report

Share on facebook
Share on twitter
Share on linkedin
Share on whatsapp

Turning Point Therapeutics Inc. (NASDAQ:TPTX) went up by 4.23% from its latest closing price compared to the recent 1-year high of $141.30. The company’s stock price has collected -1.26% of loss in the last five trading sessions. Press Release reported on 11/10/21 that Turning Point Therapeutics to Participate in Upcoming Investor Conferences

Is It Worth Investing in Turning Point Therapeutics Inc. (NASDAQ :TPTX) Right Now?

Opinions of the stock are interesting as 9 analysts out of 11 who provided ratings for Turning Point Therapeutics Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 2 rated it as “hold,” and 0 as “sell.”


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free

Sponsored


The average price from analysts is $130.00, which is $88.32 above the current price. TPTX currently public float of 47.66M and currently shorts hold a 5.85% ratio of that float. Today, the average trading volume of TPTX was 437.61K shares.

TPTX’s Market Performance

TPTX stocks went down by -1.26% for the week, with a monthly jump of 0.10% and a quarterly performance of -44.77%, while its annual performance rate touched -60.15%. The volatility ratio for the week stands at 8.20% while the volatility levels for the past 30 days are set at 6.15% for Turning Point Therapeutics Inc.. The simple moving average for the period of the last 20 days is -3.04% for TPTX stocks with a simple moving average of -43.93% for the last 200 days.

Analysts’ Opinion of TPTX

Stifel, on the other hand, stated in their research note that they expect to see TPTX reach a price target of $75. The rating they have provided for TPTX stocks is “Hold” according to the report published on September 30th, 2021.

H.C. Wainwright gave a rating of “Buy” to TPTX, setting the target price at $190 in the report published on January 19th of the current year.

TPTX Trading at -21.43% from the 50-Day Moving Average

After a stumble in the market that brought TPTX to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -70.50% of loss for the given period.

Volatility was left at 6.15%, however, over the last 30 days, the volatility rate increased by 8.20%, as shares surge +1.46% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading -46.57% lower at present.

During the last 5 trading sessions, TPTX fell by -1.26%, which changed the moving average for the period of 200-days by -69.33% in comparison to the 20-day moving average, which settled at $43.02. In addition, Turning Point Therapeutics Inc. saw -65.79% in overturn over a single year, with a tendency to cut further losses.

Insider Trading

Reports are indicating that there were more than several insider trading activities at TPTX starting from North Annette, who sale 10,000 shares at the price of $80.00 back on Aug 30. After this action, North Annette now owns 12,365 shares of Turning Point Therapeutics Inc., valued at $800,000 using the latest closing price.

Partridge Andrew John, the EVP & Chief Commercial Officer of Turning Point Therapeutics Inc., sale 1,869 shares at $74.90 during a trade that took place back on Jul 14, which means that Partridge Andrew John is holding 21,767 shares at $139,988 based on the most recent closing price.

Stock Fundamentals for TPTX

Current profitability levels for the company are sitting at:

  • -516.94 for the present operating margin

The net margin for Turning Point Therapeutics Inc. stands at -629.17. The total capital return value is set at -16.97, while invested capital returns managed to touch -20.69. Equity return is now at value -19.10, with -18.60 for asset returns.

Based on Turning Point Therapeutics Inc. (TPTX), the company’s capital structure generated 0.34 points at debt to equity in total, while total debt to capital is 0.34. Total debt to assets is 0.34, with long-term debt to equity ratio resting at 0.22. Finally, the long-term debt to capital ratio is 0.22.

>> 7 Top Picks for the Post-Pandemic Economy <<

When we switch over and look at the enterprise to sales, we see a ratio of 27.90, with the company’s debt to enterprise value settled at 0.00. The liquidity ratio also appears to be rather interesting for investors as it stands at 46.35.

Sign up for our FREE Newsletter and get:

Leave a Comment

Your email address will not be published. Required fields are marked *

Sign up for our FREE Newsletter and get:

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam

Heading

SPECIAL GIFT

WE HAVE A GIFT FOR YOU

Download Free eBook For

7 GROWTH STOCKS FOR 2021

100% free. stop anytime no spam